Orion OYJ (ORINY)
(Delayed Data from OTC)
$26.49 USD
+0.41 (1.57%)
Updated Aug 23, 2024 03:45 PM ET
1-Strong Buy of 5 1
C Value A Growth A Momentum A VGM
Price, Consensus and EPS Surprise
ORINY 26.49 +0.41(1.57%)
Will ORINY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ORINY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ORINY
Is Orion OYJ (ORINY) a Solid Growth Stock? 3 Reasons to Think "Yes"
ORINY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ORINY
Orion Oyj just upgraded at Jefferies, here's why
Bayer to seek label expansion for prostate cancer drug after late-stage trial win
Bayers to seek label expansion for prostate cancer drug after late-stage trial win
Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint
Orion is developing the Finnish life science industry in a unique collaboration project